STOCK TITAN

Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Standard BioTools Inc. (Nasdaq:LAB) introduces new automation solutions to enhance the Imaging Mass Cytometry workflow on the Hyperion XTi Imaging System, revolutionizing spatial biology in clinical and translational research. The advancements aim to increase sample throughput, provide rapid and detailed spatial analysis, and offer high-throughput tissue imaging capabilities.
Positive
  • None.
Negative
  • None.

The introduction of new automated solutions in spatial biology by Standard BioTools Inc. represents a significant stride in the field of clinical and translational research. Spatial biology, which is essential for understanding disease progression and developing targeted therapies, has been constrained by throughput limitations and manual processes. The Hyperion XTi Imaging System's new capabilities, including the automated slide loader, could substantially increase efficiency by allowing researchers to process up to 40 slides in a 24-hour period, potentially up to 10 times faster than previous methods.

The impact on the biotechnology sector could be profound, as higher throughput and automation can lead to faster hypothesis validation and quicker progression through the phases of drug development. This efficiency gain may also translate into cost savings for research institutions and pharmaceutical companies, which can now conduct large-scale studies with reduced labor costs and lower risk of manual errors. However, the adoption of these new tools will depend on their integration with existing workflows and the cost-benefit analysis that each research entity conducts.

For the stock market, such innovations can be a positive signal for investors, indicating that Standard BioTools is actively expanding its product offerings and potentially increasing its market share in the research equipment sector. The ability to produce confident data from a large number of protein markers could position the company as a leader in spatial proteomics, an emerging field with significant growth potential.

The advancements announced by Standard BioTools Inc. in the realm of Imaging Mass Cytometry (IMC) are noteworthy for the healthcare technology market. IMC is a powerful tool for the identification of biomarkers and the development of precision medicine, which is a growing focus in healthcare. The new modes of analysis provided by the Hyperion XTi Imaging System—Preview, Tissue and Cell Modes—offer researchers versatility in approaching tissue samples, which can streamline the research process.

From a market perspective, the increased automation and speed of the Hyperion XTi could encourage wider adoption of IMC technology, potentially expanding the total addressable market for Standard BioTools. The ability to connect with Laboratory Information Management Systems (LIMS) and the walk-away automation feature aligns with the broader industry trend towards digitalization and laboratory efficiency. This could make the Hyperion XTi an attractive option for laboratories looking to invest in the latest technology.

However, the long-term impact on Standard BioTools' financial performance will depend on the market's response to these innovations, including the rate of technology adoption and the competitive response from other players in the spatial biology field. Investors will be watching for customer feedback, sales growth and any shifts in market dynamics that could influence the company's stock performance.

The technological enhancements to the Hyperion XTi Imaging System are poised to have a tangible effect on the pace and quality of clinical research. The ability to visualize tissue heterogeneity quickly and conduct in-depth single-cell analysis could lead to more precise identification of disease mechanisms and therapeutic targets. This level of detail is important for advancing personalized medicine, as it allows for a deeper understanding of individual patient responses to treatments.

The new automation features, including the automated slide loader, could also improve the reproducibility of experiments by minimizing human error and variability. This standardization is essential for clinical studies that rely on consistent and reliable data to draw meaningful conclusions. The integration with LIMS further enhances data management and traceability, which is critical for regulatory compliance and quality control in clinical research.

While these advancements are promising, the true measure of their impact will be seen in the outcomes of clinical trials and research studies that utilize the Hyperion XTi. The ability to process a high volume of samples with detailed analysis may lead to more robust datasets and potentially faster drug development timelines, benefitting patients and the healthcare industry as a whole.

New advancements, including automation, aim to fast-forward spatial biology

SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced the introduction of new solutions that add automation and flexibility to the Imaging Mass Cytometry™ workflow on the Hyperion XTi™ Imaging System.

Spatial biology is vital to clinical and translational research, providing critical insights into disease progression, the identification of biomarkers, drug development and monitoring therapeutic response. Increased adoption of multiplexed tissue imaging as a spatial biology tool is driving a need for higher sample throughput. Standard BioTools™ has developed new groundbreaking capabilities to image tissue samples at never-before-seen speeds and automation, accelerating and deepening insight generation.

Hyperion™ XTi now offers three modes for rapid and detailed spatial biology analysis: (1) Preview Mode for quick whole slide overviews; (2) Tissue Mode for whole slide imaging in real time; and (3) Cell Mode to analyze regions of interest at single-cell resolution. Novel whole slide imaging using Imaging Mass Cytometry (IMC™) offers a unique opportunity to garner the most data out of limited samples with up to 10 times higher throughput than cyclic immunofluorescent imaging. By leveraging the different modes on Hyperion XTi, researchers can quickly visualize tissue heterogeneity in minutes, without having to manage time-consuming cycles, and can then conduct deeper analysis on targeted regions.

In addition, to facilitate high-throughput tissue imaging and accelerate time to results, Standard BioTools has launched a new automated slide loader that can be installed directly on Hyperion XTi for automatic loading and acquisition of up to 40 slides. This walk-away automation option eliminates manual error, reduces hands-on time and enables standardization with barcoded slide identification and LIMS connectivity.

“The innovations we are putting forth demonstrate our commitment to providing the best, most reliable and essential tools for our customers,” said Michael Egholm, PhD, President and CEO of Standard BioTools. “These new capabilities further facilitate the use of IMC across any phase of research, helping establish the technology as an unrivaled leader in spatial proteomics. Now researchers can capture all markers simultaneously in a single scan and generate confident data from 40-plus protein markers on 40 slides in 24 hours, with a fully optimized end-to-end workflow.”

About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq:LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, is driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.

For Research Use Only. Not for use in diagnostic procedures.

Limited Use Label License and other terms may apply: www.standardbio.com/legal/salesterms. Patent and License Information: www.standardbio.com/legal/notices. Trademarks: www.standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the potential benefits of a streamlined capitalization structure; our ability to attract new long-term investors and potential M&A partners; future business performance; expectations and operational and strategic plans; deployment of capital; and market and growth opportunities. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including, but not limited to, the outcome of any legal proceedings related to the merger with SomaLogic Inc.; risks that the anticipated benefits of the merger with SomaLogic Inc. or other commercial opportunities may otherwise not be fully realized or may take longer to realize than expected; risks that we may not realize expected cost savings from our restructuring, including the anticipated decrease in operational expenses, at the levels we expect; possible restructuring and transition-related disruption, including through the loss of customers, suppliers and employees and adverse impacts on our development activities and results of operation; restructuring activities, including our subleasing plans, customer and employee relations, management distraction and reduced operating performance; risks that internal and external costs required for ongoing and planned activities may be higher than expected, which may cause us to use cash more quickly than we expect or change or curtail some of our plans, or both; risks that our expectations as to expenses, cash usage and cash needs may prove not to be correct for other reasons such as changes in plans or actual events being different than our assumptions; changes in our business or external market conditions; challenges inherent in developing, manufacturing, launching, marketing and selling new products; interruptions or delays in the supply of components or materials for, or manufacturing of, our products; reliance on sales of capital equipment for a significant proportion of revenues in each quarter; seasonal variations in customer operations; unanticipated increases in costs or expenses; continued or sustained budgetary, inflationary or recessionary pressures; uncertainties in contractual relationships; reductions in research and development spending or changes in budget priorities by customers; uncertainties relating to our research and development activities, and distribution plans and capabilities; potential product performance and quality issues; risks associated with international operations; intellectual property risks; and competition. For information regarding other related risks, see the “Risk Factors” section of our annual report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 1, 2024, and in our other filings with the SEC. These forward-looking statements speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements except as may be required by law.

Contacts

Investors

David Holmes
Gilmartin Group LLC
ir@standardbio.com

Media

Nick Lamplough/Dan Moore/Tali Epstein
Collected Strategies
lab-cs@collectedstrategies.com


FAQ

What new solutions has Standard BioTools Inc. introduced for the Imaging Mass Cytometry workflow?

Standard BioTools Inc. has introduced new solutions that add automation and flexibility to the Imaging Mass Cytometry workflow on the Hyperion XTi Imaging System.

How does spatial biology play a vital role in research according to the press release?

Spatial biology provides critical insights into disease progression, biomarker identification, drug development, and therapeutic response monitoring in clinical and translational research.

What are the three modes offered by Hyperion XTi for spatial biology analysis?

Hyperion XTi offers Preview Mode for whole slide overviews, Tissue Mode for real-time whole slide imaging, and Cell Mode for single-cell resolution analysis of regions of interest.

What are the benefits of using Imaging Mass Cytometry (IMC) for tissue imaging?

IMC offers up to 10 times higher throughput than cyclic immunofluorescent imaging, allowing researchers to gather more data from samples quickly.

How does the new automated slide loader by Standard BioTools improve tissue imaging?

The automated slide loader enables automatic loading and acquisition of up to 40 slides on Hyperion XTi, reducing manual errors, hands-on time, and facilitating high-throughput imaging.

Standard BioTools Inc.

NASDAQ:LAB

LAB Rankings

LAB Latest News

LAB Stock Data

939.60M
50.24M
0.69%
56.05%
2.67%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States of America
SOUTH SAN FRANCISCO

About LAB

fluidigm (nasdaq:fldm) develops, manufactures and markets microfluidic systems for growth markets in the life sciences and in applied markets. fluidigm’s systems consist of instruments, software, integrated fluidic circuits (ifcs), high-performance assays for gene expression and genotyping, and primers for sample preparation for next-generation sequencing. fluidigm technology enables customers to perform thousands of sophisticated biochemical measurements in parallel on samples smaller than the content of a single cell, with nanoliter volumes of reagents, in half the area of a credit card. the company’s integrated customer solutions are designed to significantly simplify experimental workflows, increase throughput and reduce costs while delivering excellent data quality. based in south san francisco, fluidigm offers an exciting and collegial working environment with excellent compensation and benefits, including equity.